Key result
Thallium-201 myocardial scintigraphy demonstrated significant progression of myocardial perfusion defects in patients with hypertrophic cardiomyopathy over 8.6 years, with the extent score increasing from 17.4% to 44.0% (P<0.0001).
Why the study?
This study aimed to evaluate changes in left ventricular remodelling over time in patients with hypertrophic cardiomyopathy using thallium-201 myocardial scintigraphy.
Does thallium-201 myocardial scintigraphy predict the clinical course and left ventricular remodeling in patients with hypertrophic cardiomyopathy?
Cohort (n=48)
No
Does thallium-201 myocardial scintigraphy predict the clinical course and left ventricular remodeling in patients with hypertrophic cardiomyopathy?
Absolute Event Rate: 44% vs 17.4%
p-value: p=<0.0001
Thallium-201 myocardial scintigraphy, particularly using the mean count change index, is useful for detecting the severity of myocardial damage over time and predicting the development of left ventricular heart failure in patients with hypertrophic cardiomyopathy.
Supports serial thallium-201 scintigraphy for monitoring HCM progression; leaves open prospective validation before guiding therapy.
AIMS: This study aimed to evaluate the changes in left ventricular remodelling with time in patients with hypertrophic cardiomyopathy (HCM) using thallium-201 myocardial scintigraphy. METHODS AND RESULTS: Forty-eight patients with HCM participated in the study. The extent score (ES) and a newly devised index termed the 'mean count change' (MCC) were used to evaluate the myocardial perfusion defects. Using the amount of thallium-201 uptake (TU), MCC (%) was calculated using the following formula: (last TU - initial TU)∕initial TU × 100. To confirm the site of the lesion, the left ventricle was divided into five segments: anterior, septal, inferior, lateral, and apex. Cardiovascular complications and deaths were recorded. The mean follow-up period was 8.6 ± 2.0 years. ES increased from 17.4 ± 13.7% to 44.0 ± 22.3% (P < 0.0001). MCC increased from 0% to 12.0 ± 9.0% (P < 0.0001). The apex was the most frequent site of lesion. Twenty-seven patients (56.3%) had experienced left ventricular heart failure (LVHF). Both ES and MCC were greater in patients with LVHF than in those without LVHF. An overlap between the two groups was greater in ES than in MCC. Patients with LVHF had a higher incidence of atrial fibrillation and apoplexy. Nineteen patients (39.6%) died during the study period; 14 died from LVHF, 3 from sudden cardiac death, and 2 from cancer. CONCLUSIONS: Thallium-201 myocardial scintigraphy is useful for detecting the severity of myocardial damage and for confirming the lesion site in patients with HCM. MCC may be superior to ES in the evaluation of these changes with time.
No takes yet. Share an insight, caveat, or question.
Hamada et al. (2021) conducted a cohort in Hypertrophic cardiomyopathy (n=48). Thallium-201 myocardial scintigraphy vs. Baseline (first study) was evaluated on Extent score (ES) of myocardial perfusion defects (p=<0.0001). Thallium-201 myocardial scintigraphy demonstrated significant progression of myocardial perfusion defects in patients with hypertrophic cardiomyopathy over 8.6 years, with the extent score increasing from 17.4% to 44.0% (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: